Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annelore Altendorf-Hofmann

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Cancers|December 8, 2020
Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue SarcomaMarkus Albertsmeier, Annelore Altendorf-Hofmann, Lars H Lindner, et al.
Cancers|June 22, 2023
TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)Luc M Berclaz, Annelore Altendorf-Hofmann, Lars H Lindner, et al.
Endocrine-Related Cancer|January 5, 2019
Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasiaFlorian Bösch, Katharina Brüwer, Annelore Altendorf-Hofmann, et al.
Journal of Cancer Research and Clinical Oncology|February 18, 2017
Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinomaYue Zhao, Annelore Altendorf-Hofmann, Ioannis Pozios, et al.
British Journal of Cancer|November 2, 2016
Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trialsSteffen Ormanns, Michael Haas, Sibylle Baechmann, et al.
Oncotarget|March 24, 2015
FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumorsFranziska Briest, Erika Berg, Irina Grass, et al.
Molecular Cytogenetics|April 29, 2016
Chromosomes in a genome-wise order: evidence for metaphase architectureAnja Weise, Samarth Bhatt, Katja Piaszinski, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2021
Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trialRolf D Issels, Elfriede Noessner, Lars H Lindner, et al.
Cancer Immunology, Immunotherapy : CII|March 31, 2020
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomasMartin F Orth, Veit Leonhard Buecklein, Eric Kampmann, et al.
Molecular Oncology|February 20, 2024
ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migrationJennifer Kosinski, Antonio Sechi, Johanna Hain, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Cancers|December 8, 2020
Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue SarcomaMarkus Albertsmeier, Annelore Altendorf-Hofmann, Lars H Lindner, et al.
Cancers|June 22, 2023
TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)Luc M Berclaz, Annelore Altendorf-Hofmann, Lars H Lindner, et al.
Endocrine-Related Cancer|January 5, 2019
Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasiaFlorian Bösch, Katharina Brüwer, Annelore Altendorf-Hofmann, et al.
Journal of Cancer Research and Clinical Oncology|February 18, 2017
Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinomaYue Zhao, Annelore Altendorf-Hofmann, Ioannis Pozios, et al.
British Journal of Cancer|November 2, 2016
Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trialsSteffen Ormanns, Michael Haas, Sibylle Baechmann, et al.
Oncotarget|March 24, 2015
FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumorsFranziska Briest, Erika Berg, Irina Grass, et al.
Molecular Cytogenetics|April 29, 2016
Chromosomes in a genome-wise order: evidence for metaphase architectureAnja Weise, Samarth Bhatt, Katja Piaszinski, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2021
Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trialRolf D Issels, Elfriede Noessner, Lars H Lindner, et al.
Cancer Immunology, Immunotherapy : CII|March 31, 2020
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomasMartin F Orth, Veit Leonhard Buecklein, Eric Kampmann, et al.
Molecular Oncology|February 20, 2024
ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migrationJennifer Kosinski, Antonio Sechi, Johanna Hain, et al.
Pageof 6